Published in Br J Cancer on March 01, 2000
Melanoma: a model for testing new agents in combination therapies. J Transl Med (2010) 1.39
Gender-related differences in outcome for melanoma patients. Ann Surg (2006) 1.32
A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1). Cancer (2010) 1.22
Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM). Br J Cancer (2002) 0.97
Immunotherapy of distant metastatic disease. Ann Oncol (2009) 0.96
The history and future of chemotherapy for melanoma. Hematol Oncol Clin North Am (2009) 0.92
A(2B) and A(3) adenosine receptors modulate vascular endothelial growth factor and interleukin-8 expression in human melanoma cells treated with etoposide and doxorubicin. Neoplasia (2009) 0.91
The emerging role of the thrombin receptor (PAR-1) in melanoma metastasis--a possible therapeutic target. Oncotarget (2011) 0.87
A natural bacterial-derived product, the metalloprotease arazyme, inhibits metastatic murine melanoma by inducing MMP-8 cross-reactive antibodies. PLoS One (2014) 0.76
State of melanoma: an historic overview of a field in transition. Hematol Oncol Clin North Am (2014) 0.76
Therapeutic interventions to disrupt the protein synthetic machinery in melanoma. Pigment Cell Melanoma Res (2015) 0.75
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol (1999) 5.95
Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol (1992) 2.26
Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol (1999) 1.78
Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat Rep (1984) 1.51
Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol (1998) 1.46
The treatment of metastatic melanoma with chemotherapy and biologics. Curr Opin Oncol (1997) 1.18
Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. J Clin Oncol (1994) 1.16
Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials. Int J Cancer (1992) 1.14
Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol (1991) 1.07
Melanoma: chemotherapy. Br Med Bull (1995) 1.04
Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol (1996) 1.03
Outpatient chemoimmunotherapy for the treatment of metastatic melanoma. Semin Oncol (1997) 0.98
Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma. Br J Cancer (1998) 0.94
Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit. Br J Cancer (1990) 0.92
Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma. J Clin Oncol (1984) 0.88
Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study. J Clin Oncol (1998) 0.86
Vinblastine, infusion, bleomycin, and cis-dichlorodiammine-platinum chemotherapy in metastatic melanoma. Cancer (1981) 0.85
Dacarbazine (DTIC)-based chemotherapy or chemoimmunotherapy of patients with disseminated malignant melanoma. Br J Cancer (1994) 0.85
A phase II study of interferon-alpha 2b with dacarbazine, carmustine, cisplatin and tamoxifen in metastatic melanoma. Melanoma Res (1997) 0.79
The complete genome sequence of the gram-positive bacterium Bacillus subtilis. Nature (1997) 33.47
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol (2000) 9.70
Laboratory procedures for the isolation of chlamydia trachomatis from the human genital tract. J Clin Pathol (1975) 6.22
Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol (1997) 5.89
Single-chain antigen-binding proteins. Science (1988) 5.29
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol (2001) 5.25
The epic project: developing national evidence-based guidelines for preventing healthcare associated infections. Phase I: Guidelines for preventing hospital-acquired infections. Department of Health (England). J Hosp Infect (2001) 4.95
Chlamydial infection of the male urethra. Br J Vener Dis (1976) 4.61
Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol (2002) 3.98
Mechanisms of spontaneous and induced frameshift mutation in bacteriophage T4. Genetics (1985) 3.83
Wnt signalling required for expansion of neural crest and CNS progenitors. Nature (1997) 3.11
Factors predicting the use of breast-conserving therapy in stage I and II breast carcinoma. J Clin Oncol (2001) 2.91
Essential protective roles of reactive astrocytes in traumatic brain injury. Brain (2006) 2.75
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer (2005) 2.71
Conducting clinical research in the new NHS: the model of cancer. United Kingdom Coordinating Committee on Cancer Research. BMJ (1994) 2.70
Thoracic pedicle screw fixation in spinal deformities: are they really safe? Spine (Phila Pa 1976) (2001) 2.64
Alternate splicing produces a novel cyclin D1 transcript. Oncogene (1995) 2.48
Durable treatment-free remission after high-dose cyclophosphamide therapy for previously untreated severe aplastic anemia. Ann Intern Med (2001) 2.47
Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol (2005) 2.39
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol (2005) 2.33
Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br J Cancer (2000) 2.30
Modulation of receptive field properties of thalamic somatosensory neurons by the depth of anesthesia. J Neurophysiol (1999) 2.27
Alopecia universalis associated with a mutation in the human hairless gene. Science (1998) 2.23
Revised U.K. guidelines for the management of cutaneous melanoma 2010. Br J Dermatol (2010) 2.22
Screening and treatment of asymptomatic bacteriuria of pregnancy to prevent pyelonephritis: a cost-effectiveness and cost-benefit analysis. Obstet Gynecol (1995) 2.20
Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer (1987) 2.18
Randomized phase II study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status </= 70) and advanced non-small-cell lung cancer. J Clin Oncol (2005) 2.17
Plasma levels of beta-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo. Blood (1981) 2.17
The effect of distance from injection site to the brainstem using spinal sufentanil. Reg Anesth Pain Med (2001) 2.16
Impact of resistance to first-line and injectable drugs on treatment outcomes in MDR-TB. Eur Respir J (2009) 2.15
The virB operon of Agrobacterium tumefaciens pTiC58 encodes 11 open reading frames. Mol Gen Genet (1990) 2.14
Why do women attend familial breast cancer clinics? J Med Genet (2000) 2.13
A report on genetic registers. Based on the report of the Clinical Genetics Society Working Party. J Med Genet (1978) 2.09
The lack of effect of ampicillin plus probenecid given for genital infections with Neisseria gonorrhoeae on associated infections with Chlamydia trachomatis. J Infect Dis (1976) 2.07
Sonic hedgehog regulates proliferation and inhibits differentiation of CNS precursor cells. J Neurosci (1999) 2.02
Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer (1987) 1.97
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer (2004) 1.94
Radiotherapy patterns of care study in lung carcinoma. J Clin Oncol (2003) 1.94
Genetic predisposition to human lung cancer. Br J Cancer (1986) 1.94
Randomized trial of a specialist genetic assessment service for familial breast cancer. J Natl Cancer Inst (2000) 1.92
Control of mitochondrial redox balance and cellular defense against oxidative damage by mitochondrial NADP+-dependent isocitrate dehydrogenase. J Biol Chem (2001) 1.90
A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol (2011) 1.88
Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer (1999) 1.80
Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. J Clin Oncol (2005) 1.80
Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol (1994) 1.79
Mimicry profiles are affected by human-induced habitat changes. Proc Biol Sci (1998) 1.78
Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data. Histopathology (2006) 1.77
Comparison of surgical conditions during propofol or sevoflurane anaesthesia for endoscopic sinus surgery. Br J Anaesth (2007) 1.76
Binding of factors IX and IXa to cultured vascular endothelial cells. Proc Natl Acad Sci U S A (1983) 1.75
IgA nephropathy: morphologic predictors of progressive renal disease. Hum Pathol (1982) 1.73
Oral probiotics can resolve urogenital infections. FEMS Immunol Med Microbiol (2001) 1.73
Vaginal progesterone, cerclage or cervical pessary for preventing preterm birth in asymptomatic singleton pregnant women with a history of preterm birth and a sonographic short cervix. Ultrasound Obstet Gynecol (2013) 1.71
Volunteers or victims: patients' views of randomised cancer clinical trials. Br J Cancer (1995) 1.70
Paradoxical effects of acute ethanolism in experimental brain injury. J Neurosurg (1997) 1.64
Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. J Clin Oncol (2003) 1.62
Microsatellite instability at AAAG repeat sequences in respiratory tract cancers. Int J Cancer (2001) 1.62
Serum 6-beta-naltrexol levels are related to alcohol responses in heavy drinkers. Alcohol Clin Exp Res (2000) 1.62
Identification of amino acid residues critical for aggregation of human CC chemokines macrophage inflammatory protein (MIP)-1alpha, MIP-1beta, and RANTES. Characterization of active disaggregated chemokine variants. J Biol Chem (1999) 1.62
Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol (1995) 1.61
Terbutaline pump maintenance therapy for prevention of preterm delivery: a double-blind trial. Am J Obstet Gynecol (1998) 1.60
Complications of midtrimester pregnancy termination: the effect of prior cesarean delivery. Am J Obstet Gynecol (1996) 1.60
The near-death experience. Br J Psychiatry (1988) 1.56
Can prenatal ultrasound findings predict ambulatory status in fetuses with open spina bifida? Am J Obstet Gynecol (2001) 1.55
Estimating population size for capture-recapture data when capture probabilities vary by time and individual animal. Biometrics (1992) 1.53
Comparison of motor-evoked potentials monitoring in response to transcranial electrical stimulation in subjects undergoing neurosurgery with partial vs no neuromuscular block. Br J Anaesth (2013) 1.53
Radioisotopic assays of CoASH and carnitine and their acetylated forms in human skeletal muscle. Anal Biochem (1990) 1.50
Resistance exercise training and the orthostatic response. Eur J Appl Physiol Occup Physiol (1997) 1.50
Phenylpropanolamine contained in cold remedies and risk of hemorrhagic stroke. Neurology (2007) 1.47
Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol (1998) 1.46
Erythropoietic protoporphyria in Sweden: demographic, clinical, biochemical and genetic characteristics. J Intern Med (2011) 1.46
Expression of epidermal growth factor receptor (EGF-R) in human lung tumours. Br J Cancer (1986) 1.45
Association between body mass index and pregnancy outcome in a randomized trial of cerclage for short cervix. Ultrasound Obstet Gynecol (2012) 1.44
Pregnancy outcome following genetic amniocentesis at 11-14 versus 16-19 weeks' gestation. Obstet Gynecol (1996) 1.44
Cloning, expression, and chromosomal location of SHH and IHH: two human homologues of the Drosophila segment polarity gene hedgehog. Genomics (1995) 1.44
Criteria for failed labor induction: prospective evaluation of a standardized protocol. Obstet Gynecol (2000) 1.42
Spark erosion: a high production rate method for producing Bi(0.5)Sb(1.5)Te3 nanoparticles with enhanced thermoelectric performance. Nanotechnology (2012) 1.42
Do we pay too dearly for our sport and leisure activities? An investigation into fatalities as a result of sporting and leisure activities in England and Wales, 1982-1988. Public Health (1990) 1.42
Science and Technology Committee's report on genetics. BMJ (1995) 1.42
The effect of manual removal of the placenta on post-cesarean endometritis. Obstet Gynecol (1996) 1.42
Molecular cloning and characterization of FHL2, a novel LIM domain protein preferentially expressed in human heart. Gene (1998) 1.40
Enrichment of HFE mutations in Swedish patients with familial and sporadic form of porphyria cutanea tarda. J Intern Med (2004) 1.39
Oligohydramnios: antepartum fetal urine production and intrapartum fetal distress. Am J Obstet Gynecol (1991) 1.39
Comparison of multiple-marker screening with amniocentesis for the detection of fetal aneuploidy in women > or = 35 years old. Am J Obstet Gynecol (1995) 1.39
Significance of a false-positive trisomy 18 multiple-marker screening test. Obstet Gynecol (1997) 1.39
Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer. Br J Cancer (1996) 1.38
A phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br J Cancer (1993) 1.38
Difficult intubation due to position of laryngoscope blade light. Anaesthesia (2013) 1.38
Magnetic resonance imaging and computed tomography scan for the diagnosis of acute fatty liver of pregnancy. Am J Perinatol (1990) 1.38
Family planning: personal and political perspectives from Choiseul Province, Solomon Islands. Aust J Public Health (1995) 1.38
Carnitine administration as a tool of modify energy metabolism during exercise. Eur J Appl Physiol Occup Physiol (1991) 1.38
O6-alkylguanine-DNA alkyltransferase depletion and regeneration in human peripheral lymphocytes following dacarbazine and fotemustine. Cancer Res (1991) 1.34
The Mendelian inheritance of a human X chromosome-specific DNA sequence polymorphism and its use in linkage studies of genetic disease. Hum Genet (1982) 1.34